

11146/10904

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
3


In re application of:

Naomi L. Esmon, et al.
 Serial No.: 10/088,021
 Filed: March 14, 2002
 Group: Unassigned
 Examiner: Unassigned
 For: THROMBOTIC EPISODE RISK ASSAYS USING OXIDIZED
 PHOSPHOLIPIDS

Assistant Commissioner For Patents
 Box PCT
 Washington, D.C. 20231

EXPRESS MAIL NO. EV047873955US
 DATE OF DEPOSIT 08 July 2002

I hereby certify that this correspondence is being deposited with the United States
 Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10
 on the date indicated above and is addressed to the Assistant Commissioner for
 Patents, Box PCT, Washington, D.C. 20231 on 08 July 2002
 (Date of Deposit)

Derrick Gordon
 (Name of Depositor)

 (Signature)
 Date of Signature: 08 July 2002

Dear Sir:


INFORMATION DISCLOSURE STATEMENT

Applicants hereby submit the enclosed Information Disclosure Statement
 Pursuant to 37 C.F.R. § 1.97(b) or in the alternative, 37 C.F.R. § 1.97(c). If the first Office
 Action occurs before receipt of this document, pursuant to 37 C.F.R. § 1.97(c) and § 1.17(p),
 please withdraw the necessary fees from Deposit Account No. 18-1260.

In accordance with the requirements of 37 C.F.R. §§ 1.97 and 1.98, attached
 please find a Form PTO-1449 listing information for consideration by the Office in connection
 with its examination of the above-captioned patent application. Copies of each document listed
 are enclosed herein.

Applicants submit that no representation is made, and no representation is intended, that more relevant material does not exist, or that the order of presentation of these materials in any way reflects their relative pertinence. The listing on the attached Form PTO-1449 is not intended to constitute an admission of any kind. Specifically, this presentation is not an admission that any of the items listed are properly citable against the above-identified application as prior art.

Respectfully submitted,

By: 
Karen L. Knezek
Registration No. 39,253

KLK/eph/ld

July 8, 2002

SIDLEY & AUSTIN

717 N. Harwood, Suite 3400

Dallas, Texas 75201

(214) 981-3300

| | | | |
|--|------------|-------------------------|------------|
| U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE LIST (Use several sheets if necessary) | | ATT. DOCKET NO. | SERIAL NO. |
| | | 11146/10904 | 10/088,021 |
| | | APPLICANT | |
| | | ESMON, Naomi L., et al. | |
| | | FILING DATE | GROUP |
| 03/14/2002 | unassigned | | |

U.S. PATENT DOCUMENTS

| EXAMINER -INITIAL | | DOCUMENT NUMBER | | | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|----------------------|--|-----------------|---|---|---|---|---|----------|-----------------|-------|----------|-------------------------------|
| | | 5 | 4 | 7 | 2 | 8 | 5 | | | | | |
| AA | | | | | | | | 12/05/95 | Smirnov, et al. | CI2Q | 1/56 | 09/15/93 |
| AB | | | | | | | | | | | | |
| AC | | | | | | | | | | | | |
| AD | | | | | | | | | | | | |
| AE | | | | | | | | | | | | |
| AF | | | | | | | | | | | | |
| AG | | | | | | | | | | | | |
| AH | | | | | | | | | | | | |
| AI | | | | | | | | | | | | |
| AJ | | | | | | | | | | | | |
| AK | | | | | | | | | | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | | | | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|----|--|-----------------|----|--|--|--|--|------|---------|-------|----------|-------------|--|
| | | YES | NO | | | | | | | | | | |
| AL | | | | | | | | | | | | | |
| AM | | | | | | | | | | | | | |
| AN | | | | | | | | | | | | | |
| AO | | | | | | | | | | | | | |
| AP | | | | | | | | | | | | | |

(Including Author, Title, Date, Pertinent Pages, Etc.).

| | | |
|----|---|---|
| AR | | Aviram, et al., 1991. "Oxidized low-density lipoprotein reduces plasma coagulation in-vitro," |
| | ✓ | Scand J Lab Invest 51:17-21 |
| AS | | Barrowcliffe, et al. 1981. "Studies of phospholipid reagents used in coagulation I: general properties and their sensitivity to Factor VIII," Thromb Haemostas 46:629-633 ✓ |
| AT | | Barrowcliffe, et al. 1981. "Phospholipid reagents used in coagulation II: factors influencing their sensitivity to heparin," Thromb Haemostas 46:634-637 |

MINER

DATE CONSIDERED

MINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

| | | |
|--|--------------------------|------------|
| U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE LIST (Use several sheets if necessary) | ATT. DOCKET NO. | SERIAL NO. |
| | 11146/10904 | 10/088,021 |
| | APPLICANT | |
| | ESMON, Naomi, L., et al. | |
| | FILING DATE | GROUP |
| 03/14/2002 | unassigned | |

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|-------------------|----|-----------------|------|------|-------|----------|----------------------------|
| | BA | | | | | | |
| | BB | | | | | | |
| | BC | | | | | | |
| | BD | | | | | | |
| | BE | | | | | | |
| | BF | | | | | | |
| | BG | | | | | | |
| | BH | | | | | | |
| | BI | | | | | | |
| | BJ | | | | | | |
| | BK | | | | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION |
|--|----|-----------------|--|------|---------|-------|----------|-------------|
| | | | | | | | YES | NO |
| | BL | | | | | | | |
| | BM | | | | | | | |
| | BN | | | | | | | |
| | BO | | | | | | | |
| | BP | | | | | | | |

(Including Author, Title, Date, Pertinent Pages, Etc.).

| | | |
|----|---|--|
| BR | ✓ | Billy, et al. 1995. "Prothrombin contributes to the assembly of the factor Va-factor Xa complex at phosphatidylserine-containing phospholipid membranes," <i>J Biol Chem</i> 270:26883-26889 |
| BS | ✓ | Esmon, C.T. and Schwarz, H.P. 1995. "An update on clinical and basic aspects of the protein C anticoagulant pathway," <i>Trends Cardiovasc Med</i> 5:141-148 |
| BT | ✓ | Esmon, et al. 2000. "Antiphospholipid antibodies and the protein C pathway," <i>J Autoimmunity</i> 15:221-225 |

DATE CONSIDERED

| | |
|---|--|
| EXAMINER | |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. | |

| | | |
|--|--------------------------|------------|
| U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE LIST (Use several sheets if necessary) | ATT. DOCKET NO. | SERIAL NO. |
| | 11146/10904 | 10/088,021 |
| | APPLICANT | |
| | ESMON, Naomi, L., et al. | |
| | FILING DATE | GROUP |
| 03/14/2002 | unassigned | |

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|-------------------|-----------------|------|------|-------|----------|----------------------------|
| CA | | | | | | |
| CB | | | | | | |
| CC | | | | | | |
| CD | | | | | | |
| CE | | | | | | |
| CF | | | | | | |
| CG | | | | | | |
| CH | | | | | | |
| CI | | | | | | |
| CJ | | | | | | |
| CK | | | | | | |

FOREIGN PATENT DOCUMENTS

| | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION |
|----|-----------------|------|---------|-------|----------|-------------|
| CL | | | | | | YES NO |
| CM | | | | | | |
| CN | | | | | | |
| CO | | | | | | |
| CP | | | | | | |

(Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|----|---|---|
| CR | | Furie, B. and Furie, B.C. 1988. "The molecular basis of blood coagulation," |
| | ✓ | Cell 53:505-518 |
| CS | | Gilbert, G.E. and Arena, A.A. 1995. "Phosphatidylethanolamine induces high affinity binding sites for factor VIII on membranes containing phosphatidyl-L-serine," J Biol Chem 270:18500-18505 |
| CT | | Horkko, et al. 1996. "Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids," |
| | | J Clin Invest 98:815-825 |

DATE CONSIDERED

EXAMINER
 *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

| | | |
|---|--------------------------|------------|
| U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE LIST (Use several sheets if necessary) | ATT. DOCKET NO. | SERIAL NO. |
| | 11146/10904 | 10/088,021 |
| | APPLICANT | |
| | ESMON, Naomi, L., et al. | |
| FILING DATE | GROUP | |
| 03/14/2002 | unassigned | |

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|-------------------|----|-----------------|------|------|-------|----------|----------------------------|
| | DA | | | | | | |
| | DB | | | | | | |
| | DC | | | | | | |
| | DD | | | | | | |
| | DE | | | | | | |
| | DF | | | | | | |
| | DG | | | | | | |
| | DH | | | | | | |
| | DI | | | | | | |
| | DJ | | | | | | |
| | DK | | | | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION |
|--|----|-----------------|------|---------|-------|----------|-------------|
| | | | | | | | YES NO |
| | DL | | | | | | |
| | DM | | | | | | |
| | DN | | | | | | |
| | DO | | | | | | |
| | DP | | | | | | |

(Including Author, Title, Date, Pertinent Pages, Etc.).

| | | |
|----|---|--|
| DR | | Jain, S.K. 1985. "In vivo externalization of phosphatidylserine and phosphatidylethanolamine in the membrane |
| | ✓ | bilayer and hypercoagulability by the lipid peroxidation of erythrocytes in rats," <i>J Clin Invest</i> 76:281-286 |
| DS | | Lesnik, et al. 1995. "Tissue factor pathway inhibitor activity associated with LDL is inactivated by cell- and |
| | ✓ | copper-mediated oxidation," <i>Arteriosclerosis, Thrombosis and Vascular Biology</i> 15:1121-1130 |
| DT | | Malech, H.L. and Gallin, J.I. 1987. "Neutrophils in human diseases," |
| | ✓ | <i>N Engl J Med</i> 317:687-694 |

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

| | | | |
|--|--|--------------------------|------------|
| U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE LIST (Use several sheets if necessary) | | ATT. DOCKET NO. | SERIAL NO. |
| | | 11146/10904 | 10/088,021 |
| | | APPLICANT | |
| | | ESMON, Namoi, L., et al. | |
| FILING DATE 03/14/2002 | | GROUP | |
| | | unassigned | |

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|-------------------|----|-----------------|------|------|-------|----------|----------------------------|
| | EA | | | | | | |
| | EB | | | | | | |
| | EC | | | | | | |
| | ED | | | | | | |
| | EE | | | | | | |
| | EF | | | | | | |
| | EG | | | | | | |
| | EH | | | | | | |
| | EI | | | | | | |
| | EJ | | | | | | |
| | EK | | | | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION |
|--|----|-----------------|------|---------|-------|----------|-------------|
| | | | | | | | YES NO |
| | EL | | | | | | |
| | EM | | | | | | |
| | EN | | | | | | |
| | EO | | | | | | |
| | EP | | | | | | |

(Including Author, Title, Date, Pertinent Pages, Etc.).

| | | |
|----|---|---|
| ER | | Mann, et al. 1988. "Cofactor proteins in the assembly and expression of blood clotting enzyme complexes," |
| | ✓ | <i>Ann Rev Biochem</i> 57:915-956 |
| ES | ✓ | McCord, J.M. 1985. "Oxygen-derived free radicals in postischemic tissue injury," |
| | ✓ | <i>N Engl J Med</i> 312:159-163 |
| ET | | Neuenschwander, et al. 1995. "Phosphatidylethanolamine augments factor VIIa-tissue factor activity: enhancement of sensitivity to phosphatidylserine," <i>Biochemistry</i> 34:13988-13993 |

| EXAMINER | DATE CONSIDERED |
|---|-----------------|
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. | |

| | | |
|--|--------------------------|------------|
| U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE LIST (Use several sheets if necessary) | ATT. DOCKET NO. | SERIAL NO. |
| | 11146/10904 | 10/088,021 |
| | APPLICANT | |
| | ESMON, Naomi, L., et al. | |
| FILING DATE | GROUP | |
| 03/14/2002 | unassigned | |

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|-------------------|----|-----------------|------|------|-------|----------|----------------------------|
| | FA | | | | | | |
| | FB | | | | | | |
| | FC | | | | | | |
| | FD | | | | | | |
| | FE | | | | | | |
| | FF | | | | | | |
| | FG | | | | | | |
| | FH | | | | | | |
| | FI | | | | | | |
| | FJ | | | | | | |
| | FK | | | | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION |
|--|----|-----------------|------|---------|-------|----------|-------------|
| | | | | | | | YES NO |
| | FL | | | | | | |
| | FM | | | | | | |
| | FN | | | | | | |
| | FO | | | | | | |
| | FP | | | | | | |

(Including Author, Title, Date, Pertinent Pages, Etc.).

| | | |
|----|--|---|
| FR | | Pei, et al. 1993. "Specific contribution of different phospholipid surfaces to the activation of prothrombin by the fully assembled prothrombinase," <i>J Biol Chem</i> 268:3226-3233 |
| FS | | Rauch, et al. 1986. "Human hybridoma lupus anticoagulants distinguish between lamellar and hexagonal phase lipid systems," <i>J Biol Chem</i> 261: 9672-9677 |
| FT | | Smeets, et al. 1996. "Contribution of different phospholipid classes to the prothrombin converting capacity of sonicated lipid vesicles," <i>Thromb Res</i> 81:419-426 |

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

| | | |
|--|--------------------------|------------|
| U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE LIST (Use several sheets if necessary) | ATT. DOCKET NO. | SERIAL NO. |
| | 11146/10904 | 10/088,021 |
| | APPLICANT | |
| | ESMON, Naomi, L., et al. | |
| | FILING DATE | GROUP |
| 03/14/2002 | unassigned | |

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|-------------------|----|-----------------|------|------|-------|----------|----------------------------|
| | GA | | | | | | |
| | GB | | | | | | |
| | GC | | | | | | |
| | GD | | | | | | |
| | GE | | | | | | |
| | GF | | | | | | |
| | GG | | | | | | |
| | GH | | | | | | |
| | GI | | | | | | |
| | GJ | | | | | | |
| | GK | | | | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|--|----|-----------------|------|---------|-------|----------|-------------|----|
| | | | | | | | YES | NO |
| | GL | | | | | | | |
| | GM | | | | | | | |
| | GN | | | | | | | |
| | GO | | | | | | | |
| | GP | | | | | | | |

(Including Author, Title, Date, Pertinent Pages, Etc.).

| | | |
|----|--|---|
| GR | | Smirnov, M.D. and Esmon, C.T. 1994. "Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein," <i>J Biol Chem</i> 269:816-819 |
| GS | | Smirnov, et al. 1995. "On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies," <i>J Clin Invest</i> 94:309-316 |
| GT | | Smirnov, et al. 1999. "The effect of membrane composition on the hemostatic balance," <i>Biochem</i> 38:3591-3598 |

DATE CONSIDERED

EXAMINER _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.